

Reduce the Risk: PCI Bleed

A Campaign of the American College of Cardiology



Reduce the Risk: PCI Bleed

A Campaign of the American College of Cardiology

ACC Reduce the Risk: PCI Bleed Campaign: A New Tool "Insight on implementing the 2020 ACC Expert Consensus Decision Pathway for Management of Bleeding"

May 5, 2021 12-1pm ET

Webinar #9



Agenda

- Campaign Updates
- Introduction of the New Campaign Tool
- Q& A
- Announcements



Campaign Celebrations!


- Enrollment completed with 206 participants
- Final Campaign Data Submission completed
- Assessment, Toolkit and Webinars will remain available to all registry participants
- New Tool added to the Campaign Toolkit



Reduce the Risk: PCI Bleed Toolkit

Home ACC Quality Summit About Get Started Nor Quality Improvement for Institutions Home ACC Quality Summit About Get Started Nor Search REGISTER FOR CY QUA				
NCDR ACCREDITATION		CAMPAIGNS	CLINICAL TOOLKITS	LOG IN/LOG OUT
Home > Campaigns > Reduce the Risk: PCI Bleed Reduce the Risk > About Reduce the Risk > Getting Started > Reduce the Risk Features Assessment Toolkit Webinars Reduce the Risk Listserv Reduce the Risk - PCI Bleed Participation Certificate	Reduce Anticip The ACC's R the Risk: PC Quality Cam focused on minimizing F associated b risks and sav patient lives widespread of evidence- best practice Building on t ACC's prove	I Bleed apaign is PCI- leeding ring through adoption based es. the in track	ves. Reduce the Risk: PCI Bleed A Campaign of the American College of Cardiology	ACTIVATE YOUR CVQUALITY ACCOUNT Start now with your ACC login, or register to create your individual account for access. GO
ADVERTISEMENT	record in helping hospitals and cardiovascular professionals take advantage of key strategies to close gaps in guideline- recommended care, Reduce the Risk: PCI Bleed leverages the power of the CathPCI Registry® to help hospitals and clinicians			

Reduce the Risk: PCI Bleed Toolkit



Your team working

Reduce the Risk: PCI Bleed Toolkit

Assessment Toolkit Webinars Reduce the Risk Listserv Reduce the Risk - PCI Bleed **Participation Certificate** ADVERTISEMENT HeartCARE Center^{*} NATIONAL DISTINCTION OF EXCELLENCE Earn THE ULTIMAT **RECOGNITION** for Your Hard Work & Dedication to Patients Achieve the Distinction that Matters.

- > Preprocedural (Tools to address Metrics #1,3,4,5, and 6)
- Intraprocedural (Tools to address Metrics #1, 5, and 6)
- Postprocedural (Tools to address Metrics #1, 3, 5, and 6)
- ✓ Pharmacotherapy (Tools to address Metrics #1, 2, 3, 4, 5, 6)

Metric	Tools	
Metric 1: in-hospital risk-standardized rate of bleeding events for all PCI patients Metric 4: Anticoagulation utilization	General Considerations for Anticoagulation and Antiplatelet Therapy in PCI	
Metric 1: in-hospital risk-standardized rate of bleeding events for all PCI patients Metric 4: Anticoagulation utilization	Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With NVAF	
 Metric 1: in-hospital risk-standardized rate of bleeding events for all PCI patients Metric 4: Anticoagulation utilization Metric 2: Proportion of PCI procedures with transfusion of whole blood or red blood cells 	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoin 2020 Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants	

EXPERT CONSENSUS DECISION PATHWAY

2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

A Report of the American College of Cardiology Solution Set Oversight Committee


Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS AQ Cardiology

Professor and Chair Department of Pharmacy Practice School of Pharmacy and Pharmaceutical Sciences Binghamton University

Ty Gluckman, MD, FACC


Medical Director Center for Cardiovascular Analytics, Research, and Data Science (CARDS) Providence Health Institute






DOAC = direct-acting oral anticoagulant; OAC = oral anticoagulant, including DOACs and VKAs; PCC = prothrombin complex concentrate; RBC = red blood cell; VKA = vitamin K antagonist *Reversal/hemostatic agents include repletion strategies such as PCCs, plasma, vitamin K, and specific reversal agents for DOACs (e.g., idarucizumab for dabigatran; andexanet alfa for apixaban or rivaroxaban).










andexanet alfa – initial IV Bolus 800 mg at a target rate of 30 mg/min, followed by IV infusion 8 mg/min for up to 120 minutes. #ANNEXA-4 full report excluded patients with DOAC levels <75 ng/ml because those patients were considered to have clinically insufficient levels for reversal agent. If drug effect/ level can be assessed without compromising urgent clinical care decisions, then assessment should be performed before andexanet alfa is administered ## In patients taking betrixaban or edoxaban, administer high dose andexanet alfa – initial IV Bolus 800 mg at a target rate of 30 mg/min, followed by IV infusion 8 mg/min for up to 120 minutes.

1. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma controlled, phase IIIb study. Circulation 2013; 128:1234–43.







EXPERT CONSENSUS DECISION PATHWAY

2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease

A Report of the American College of Cardiology Solution Set Oversight Committee

Writing Committee Dharam J. Kumbhani, MD, SM, FACC, Chair Christopher P. Cannon, MD, FACC, Vice-Chair

Craig J. Beavers, PHARMD, FACC Deepak L. Bhatt, MD, MPH, FACC Adam Cuker, MD, MS Ty J. Gluckman, MD, FACC Joseph E. Marine, MD, FACC Roxana Mehran, MD, FACC Steven R. Messe, MD Nimesh S. Patel, MD Benjamin E. Peterson, MD, MPH Kenneth Rosenfield, MD, FACC Sarah A. Spinler, PHARMD, AACC Vinod H. Thourani, MD, FACC


Solution Set Oversight

Committee


Ty J. Gluckman, MD, FACC, Chair

Niti R. Aggarwal, MD, FACC Nicole M. Bhave, MD, FACC Gregory J. Dehmer, MD, MACC Olivia N. Gilbert, MD, MSc, FACC Chayakrit Krittanawong, MD Dharam J. Kumbhani, MD, SM, FACC Andrea L. Price, CPHQ, RCIS, AACC Javier A. Sala-Mercado, MD, PhD David E. Winchester, MD, MS, FACC Martha Gulati, MD, MS, FACC–Ex Officio











Proceed to discharge steps within original pathway

significant risk of infarction or death. For stable inpatients, the procedure is performed during hospitalization for convenience, NOT because it is urgent or emergent. Urgent: Procedure should be performed on an inpatient

DOAC

LMWH

VKA

Acid Blockers


H. Blocker

basis prior to discharge due to significant risk of ischemia, infarction, and/or death.

Emergent: Procedure should be performed as soon as possible due to substantial concerns that ongoing ischemia and/or infarction could lead to death. "As soon as possible" refers to a patient of sufficient acuity to warrant canceling a scheduled case to perform procedure immediately in the next available room during business hours, or to activate the on-call team during off-hours.

- * Some catheterization labs may use a lower threshold (e.g., ≤1.5).
- Specific reversal agents can be considered.
- IV UFH should be initiated prior to cath lab arrival for those awaiting urgent PCI for an NSTE-ACS while no longer on therapeutic anticoagulation.
- § ASA 325 mg × 1 for elective PCI; ASA 162-324 mg × 1 for urgent/emergent PCI.
- I If thrombotic risk is high and bleeding risk is low, can continue ASA 81 mg daily (as part of triple therapy) for up to 30 days.

INR = international normalized ratio; IV = intravenous; NSTE-ACS = non-ST-elevation acute coronary syndrome; PCI = percutaneous coronary intervention; UFH = unfractionated heparin.





Check out the additional ECD Figures

- Figure 5: Patient with Prior VTE Being Considered for PCI: Peri-PCI and Hospital Discharge Management of Antithrombotic Therapy
- Figure 6a and 6b: Patient With VTE on AC Who Has Undergone PCI
- Figure 7: Patient on APT With New VTE: Management of Initial Antithrombotic Therapy at Discharge









Announcements & Important Dates

- Call for Quality Summit Abstracts: Abstract Submission deadline is 11:59 PM ET on *Wednesday, June 30, 2021*
- Dashboard active until August 31, 2021
- Listserv active until August 31, 2021
- ACC Quality Summit will be virtual September 29- October 1, 2021
- Assessment, Toolkit and Webinars will remain available to all registry participants

2020 Quality Summit: 1st Place



2020 Quality Summit: People's Choice





AMERICAN COLLEGE of CARDIOLOGY